Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2022-09-19 M&A Activity
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT : acquisition de Versantis AG, société biopharmaceutique de phase clinique, pour enrichir son portefeuille de produits dans les maladies du foie
M&A Activity Classification · 99% confidence The document is a press release announcing a significant corporate action: GENFIT's acquisition of Versantis AG. It details the strategic rationale, financial terms (initial payment, potential milestones, PRV share), and includes quotes from management. This type of announcement, detailing corporate financing, M&A activity, or major structural changes, falls under Capital/Financing Update (CAP) or M&A Activity (TAR). Since the core event is the acquisition of another company to enrich the portfolio, TAR (Merger/Takeover Activity) is the most specific fit. It is not a standard regulatory filing like 10-K, an earnings release (ER), or a simple announcement of a report (RPA). The document is comprehensive, not just a brief notice.
2022-09-19 French
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases
M&A Activity Classification · 99% confidence The document is a press release announcing a significant corporate action: GENFIT's agreement to acquire Versantis. It details the strategic rationale, the assets being acquired (VS-01, VS-02), the financial terms (CHF40 million initial payment plus contingent payments), and includes forward-looking statements typical of such announcements. This type of announcement, detailing a merger or acquisition proposal, directly corresponds to the M&A Activity category. It is not an Annual Report (10-K), an Earnings Release (ER), or an Interim Report (IR) as it focuses on a transaction rather than periodic financial performance reporting. It is not a Report Publication Announcement (RPA) because it is the primary announcement of the transaction itself, not just a notice that a report is available. Therefore, the most appropriate classification is TAR (M&A Activity).
2022-09-19 English
La FDA accorde la désignation d’Orphan Drug à GNS561 pour le traitement du cholangiocarcinome
Earnings Release Classification · 95% confidence The document is a press release from GENFIT, dated September 13, 2022, announcing that the FDA granted Orphan Drug designation to its compound GNS561 for the treatment of cholangiocarcinoma. This type of announcement, detailing a specific regulatory milestone (Orphan Drug designation) and providing clinical/pipeline updates, is characteristic of an Earnings Release (ER) or a general press release related to corporate/pipeline news. Since it is an initial announcement of a significant event (not a full financial report like 10-K or IR, nor a transcript or presentation), the most appropriate classification among the provided options is 'Earnings Release' (ER), as these often contain key operational and regulatory highlights, or 'Regulatory Filings' (RNS) if it were a more generic filing. Given the content focuses on a major regulatory achievement and pipeline progress, ER is a strong fit for a high-level announcement, though RNS is also plausible as a general regulatory announcement. However, ER is typically used for significant news releases that are not strictly mandated SEC forms. Since it is a press release announcing a regulatory event, and not a full financial report, ER is selected as the best fit for a key operational update release. FY 2022
2022-09-13 French
FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Regulatory Filings Classification · 100% confidence The document is a press release dated September 13, 2022, announcing that the FDA granted Orphan Drug Designation to GENFIT's drug candidate GNS561 for cholangiocarcinoma. It details the drug, the disease, and provides company background and forward-looking statements. This type of announcement, which communicates a specific, material event or development to the public and investors, is typically classified as an Earnings Release (ER) if it were financial results, or more generally, a Regulatory Filing (RNS) if it's a broad announcement not covered by other specific categories like DIV, CAP, or MANG. Since this is a specific regulatory milestone announcement (FDA designation) that is not a full financial report (10-K, IR) or a management discussion (MDA), and it's not a proxy/voting document, the most appropriate general category for a material, non-financial regulatory update that doesn't fit elsewhere is Regulatory Filings (RNS). However, given the context of biopharma press releases announcing clinical/regulatory milestones, these often function similarly to an Earnings Release (ER) in terms of immediate market impact, but ER is strictly defined as financial results. Since this is a specific regulatory event announcement, and not a general regulatory filing fallback, I will check if there is a better fit. None of the specific codes (AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, POS) fit this specific type of press release announcing a regulatory designation. Therefore, the fallback category, Regulatory Filings (RNS), is the most suitable classification for this material, non-financial, non-presentation announcement.
2022-09-13 English
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
Transaction in Own Shares Classification · 98% confidence The document is titled "GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial" (GENFIT: Semi-annual statement of the liquidity contract concluded with Crédit Industriel et Commercial). It details the activity (shares bought/sold, transactions, capital involved) under a liquidity contract for the first semester of 2022 (S1 2022), ending June 30, 2022. This type of disclosure, which reports on the execution of a share buyback/liquidity agreement, directly relates to the company's own shares transactions. The most fitting category is 'Transaction in Own Shares' (POS). It is not a full Annual Report (10-K), an Earnings Release (ER), or a Quarterly Report (IR), as it focuses specifically on the liquidity agreement mechanics rather than overall financial performance.
2022-07-08 French
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Capital/Financing Update Classification · 99% confidence The document is titled "GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial" and is dated July 08, 2022. It explicitly details the resources on the liquidity account as of June 30, 2022, and the trading activity during the 'first half of 2022'. This content strongly indicates a periodic financial disclosure covering a period shorter than a full year (H1 2022). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although the document discusses a liquidity contract, the core content is a summary of financial/trading activity over a defined interim period (H1 2022), making it an Interim Report rather than a general transaction report (POS) or a general regulatory filing (RNS). It is not a full Annual Report (10-K) as it covers only six months.
2022-07-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.